MENA Fabry Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, and By Country

Description

List of Tables

The MENA Fabry disease treatment market size is expected to reach USD 295.32 million by 2034, according to a new study by Polaris Market Research. The report "MENA Fabry's Disease Treatment Market Size, Share, & Industry Analysis Report By Route of Administration (Intravenous Route and Oral Route), By Therapy, By Distribution Channel, By Country - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The MENA Fabry's disease treatment market focuses on delivering specialized therapeutic solutions for an X-linked lysosomal storage disorder characterized by deficient alpha-galactosidase A enzyme activity. The market is gaining momentum through a combination of increasing clinical awareness, expanding molecular diagnostic infrastructure, and evolving reimbursement models that facilitate access to high-cost biologics. Pharmaceutical R&D pipelines are being diversified to include next-generation therapies such as substrate reduction options and gene therapies that promise longer-lasting efficacy with reduced dosing frequency. Strategic investments in precision medicine and expanded newborn screening programs are enabling early intervention and improving clinical outcomes. Industry trends reflect a shift toward oral therapeutics that enhance patient adherence while minimizing infusion-related complications. Advanced health IT integration, including digital patient monitoring devices, is also enhancing physician decision-making and personalized care strategies.

Opportunities exist in local bio manufacturing and public-private partnerships that aim to bridge treatment gaps and reduce therapy costs. Stakeholders are leveraging regulatory harmonization efforts and rare disease frameworks to expedite market entry for novel therapeutics. The emergence of specialty distribution networks and cross-border collaborations is fostering more efficient supply chains. Rising engagement from advocacy groups and regional medical societies is also playing a critical role in shaping policy reforms and supporting equitable access. As treatment paradigms evolve, the market is expected to witness an upsurge in value-based healthcare delivery models that prioritize outcomes-driven care. The convergence of clinical innovation, policy support, and infrastructure development is positioning this market for sustained, technology-driven growth across multiple therapeutic modalities.

MENA Fabry's Disease Treatment Market Report Highlights

By route of administration, in 2024, the intravenous route segment was valued at USD 110 million. The segment growth is attributed to the established use of enzyme replacement therapies (ERTs) that require infusion-based delivery

Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment was valued at approximately USD 115 million. The demand for ERT is driven by its status as the most established therapeutic approach for Fabry's disease.

The Saudi Arabia Fabry's disease treatment market accounts for approximately 31% of the total regional revenue share, driven by the government's strong investments in rare disease care.

The Egypt Fabry's disease treatment market is projected to register a CAGR of 6.2% from 2025 to 2034, largely fueled by improved diagnostic capacity and greater public-private collaboration.

A few key players include Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Chiesi Farmaceutici S.p.A.; Idorsia Pharmaceuticals Ltd.; ISU ABXIS Co., Ltd.; JCR Pharmaceuticals Co., Ltd.; Protalix Biotherapeutics Inc.; Sangamo Therapeutics, Inc.; Sanofi; and Takeda Pharmaceutical.

Polaris Market Research has segmented the MENA Fabry's disease treatment market report on the basis of route of administration, therapy, distribution channel, and country:

By Route of Administration Outlook (Revenue USD Million, 2020-2034)

Intravenous Route

Oral Route

By Therapy Outlook (Revenue USD Million, 2020-2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue USD Million, 2020-2034)

Saudi Arabia

Turkey

Iran

Egypt

Algeria

Morocco

Iraq

Libya

Rest of MENA

Product Code: PM5774

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. MENA Fabry Disease Treatment Market Insights

4.1. MENA Fabry Disease Treatment Market - Market Snapshot
4.2. MENA Fabry Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Improved Genetic Testing Infrastructure
  - 4.2.1.2. Growth in Health Insurance Penetration
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Lack of Awareness
4.3. Porter Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. MENA Fabry Disease Treatment Market Trends
4.6. Value Chain Analysis

5. MENA Fabry Disease Treatment Market, by Route of Administration

5.1. Key Findings
5.2. Introduction
- 5.2.1. MENA Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
5.3. Intravenous Route
- 5.3.1. MENA Fabry Disease Treatment Market, by Intravenous Route, by Country, 2020-2034 (USD Million)
5.4. Oral Route
- 5.4.1. MENA Fabry Disease Treatment Market, by Oral Route, by Country, 2020-2034 (USD Million)

6. MENA Fabry Disease Treatment Market, by Therapy

6.1. Key Findings
6.2. Introduction
- 6.2.1. MENA Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
6.3. Enzyme Replacement Therapy (ERT)
- 6.3.1. MENA Fabry Disease Treatment Market, by Enzyme Replacement Therapy (ERT), by Country, 2020-2034 (USD Million)
6.4. Substrate Reduction Therapy (SRT)
- 6.4.1. MENA Fabry Disease Treatment Market, by Substrate Reduction Therapy (SRT), by Country, 2020-2034 (USD Million)
6.5. Others
- 6.5.1. MENA Fabry Disease Treatment Market, by Others, by Country, 2020-2034 (USD Million)

7. MENA Fabry Disease Treatment Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. MENA Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
7.3. Hospital Pharmacies
- 7.3.1. MENA Fabry Disease Treatment Market, by Hospital Pharmacies, by Country, 2020-2034 (USD Million)
7.4. Retail Pharmacies
- 7.4.1. MENA Fabry Disease Treatment Market, by Retail Pharmacies, by Country, 2020-2034 (USD Million)
7.5. Online Pharmacies
- 7.5.1. MENA Fabry Disease Treatment Market, by Online Pharmacies, by Country, 2020-2034 (USD Million)

8. MENA Fabry Disease Treatment Market, by Country

8.1. Key Findings
8.2. Introduction
8.3. MENA Fabry Disease Treatment Market
- 8.3.1. Middle East & Africa: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
- 8.3.2. Middle East & Africa: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
- 8.3.3. Middle East & Africa: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.4. Fabry Disease Treatment Market - Saudi Arabia
  - 8.3.4.1. Saudi Arabia: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
  - 8.3.4.2. Saudi Arabia: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
  - 8.3.4.3. Saudi Arabia: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.5. Fabry Disease Treatment Market - UAE
  - 8.3.5.1. UAE: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
  - 8.3.5.2. UAE: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
  - 8.3.5.3. UAE: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.6. MENA Fabry Disease Treatment Market - Israel
  - 8.3.6.1. Israel: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
  - 8.3.6.2. Israel: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
  - 8.3.6.3. Israel: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.7. Fabry Disease Treatment Market - South Africa
  - 8.3.7.1. South Africa: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
  - 8.3.7.2. South Africa: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
  - 8.3.7.3. South Africa: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)
- 8.3.8. Fabry Disease Treatment Market - Rest of Middle East & Africa
  - 8.3.8.1. Rest of Middle East & Africa: Fabry Disease Treatment Market, by Route of Administration, 2020-2034 (USD Million)
  - 8.3.8.2. Rest of Middle East & Africa: Fabry Disease Treatment Market, by Therapy, 2020-2034 (USD Million)
  - 8.3.8.3. Rest of Middle East & Africa: Fabry Disease Treatment Market, by Distribution Channel, 2020-2034 (USD Million)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Amicus Therapeutics, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. CANbridge Life Sciences Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Chiesi Farmaceutici S.p.A.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Idorsia Pharmaceuticals Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. ISU ABXIS Co., Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. JCR Pharmaceuticals Co., Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Protalix Biotherapeutics Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Sangamo Therapeutics, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Takeda Pharmaceutical
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development